There is 1 paper on cardiorenal risk in aging research: none in people yet, 1 review.
1 paper studies it50 more mention it
16 new papers in 30 daysSee all 51 papers on cardiorenal risk
Latest
40 papers in 12 monthsDiabetology & Metabolic Syndrome
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes with CKD stages 2-4: a target trial emulation
Cohort study of 28,824 peopleGLP-1 receptor agonists
AHA Scientific Sessions 2026 Abstract
Health Economic Value of Reducing Initiation Delays of Guideline-Directed Therapies for Improving Cardiovascular and Renal Outcomes for Complex Patients with Type 2 Diabetes
Computational studyType 2 diabetes
AHA Scientific Sessions 2026 Abstract
Implementation of Kidney-Protective Therapies and Renal Outcomes in Heart Failure with Diabetic Kidney Disease: A Multicenter Cohort Study
Cohort study of 1,076 peopleDiabetic kidney disease
AHA Scientific Sessions 2026 Abstract
Initial SGLT2 Inhibitor Therapy Followed by GLP-1 Receptor Agonist Addition versus Reverse Sequencing and Cardiorenal Outcomes in Adults with Type 2 Diabetes and CKD Stages 3-4: A Propensity-Matched Real-World Analysis
Cohort study of 37,830 peopleSGLT2 inhibitors
AHA Scientific Sessions 2026 Abstract
Trends and Disparities in Hypertensive Heart and Renal Disease Mortality: A CDC WONDER Analysis, 1999 to 2024
Cross-sectional study of 250,741 peoplePopulations
AHA Scientific Sessions 2026 Abstract
Isolated Diastolic Hypertension in the Presence of Metabolic Dysfunction: A Higher-Risk Phenotype?
Cohort study of 28,901 peopleIsolated diastolic hypertension
Annals of Medicine and Surgery
Early finerenone and sodium-glucose cotransporter 2 inhibitor therapy in diabetic kidney disease: a risk-readiness-reassessment framework
CommentarySGLT2 inhibitors
European Journal of Clinical Pharmacology
Clinical pharmacology of antidiabetic drugs: an update
ReviewInterventions
Current Opinion in Nephrology and Hypertension
A practical framework for using GLP-1 RAs, SGLT2i, and MRAs with contemporary immunosuppression in kidney transplant recipients
ReviewSGLT2 inhibitors